Comparison of the Toxicity of a Single Session versus Multiple Radiation Therapy Sessions for the Treatment of Metastases
Résumé de l'étude
Since the 1990s, a radiation technique known as stereotactic body radiation therapy (SBRT) has been used for the local treatment of metastases, particularly in the brain, bones, lungs, liver, neck, lymph nodes, or other soft tissues. There are various ways to perform SBRT. In most cases, each metastasis is treated by administering a low radiation dose multiple times in succession, a technique referred to as SBRT with multiple fractions. Another technique involves administering a high radiation dose in a single session. Although this technique, known as SBRT with single fraction, may have several advantages (i.e., fewer hospital visits, less financial and logistical burden), it is still rarely used in clinical practice. In this sub-study, we investigate whether the administration of a high radiation dose in a single session (i.e., SBRT with single fraction) is as safe and effective for the treatment of oligometastases as the administration of several lower radiation doses (i.e., SBRT with multiple fractions).
(BASEC)
Intervention étudiée
We investigate whether the administration of a high radiation dose in a single session (i.e., SBRT with single fraction) is as safe and effective for the treatment of oligometastases as the administration of several lower radiation doses (i.e., SBRT with multiple fractions).
(BASEC)
Maladie en cours d'investigation
oligometastatic tumor disease
(BASEC)
oligometastatic tumor disease, a condition where cancer has spread from its original site to other parts of the body (new tumors referred to as oligometastases) (BASEC)
Critères d'exclusion
None (BASEC)
Lieu de l’étude
Berne, Zurich
(BASEC)
Sponsor
non disponible
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Dr. med. Matthias Guckenberger
+41442552930
Matthias.Guckenberger@clutterusz.ch(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale de Zurich
(BASEC)
Date d'approbation du comité d'éthique
14.03.2025
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
non disponible
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible